Stock Events

Stock Events

Voyager Therapeutics 

$3.38
71
-$0.16-4.52% Thursday 20:00
+$0.04+1.18%Thursday 23:30After hours

Statistics

Day High
3.37
Day Low
3.36
52W High
5.55
52W Low
2.94
Volume
33,458
Avg. Volume
-
Mkt Cap
208.27M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

10NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.59
-0.52
-0.44
-0.37
Expected EPS
-0.419148
Actual EPS
N/A

Financials

-296.53%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
40.37MRevenue
-119.72MNet Income

Analyst Ratings

25.00Average Price Target
The highest estimate is 25.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow VYGR. It's not an investment recommendation.
NVIDIA
12
NVDA
Tesla
11
TSLA
Amazon
10
AMZN
Meta Platforms
10
META

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biogen
BIIB
Mkt Cap32.28B
Biogen focuses on neurological diseases, directly competing in Voyager's therapeutic areas, including gene therapy.
Sarepta Therapeutics
SRPT
Mkt Cap2.2B
Sarepta Therapeutics focuses on the discovery and development of RNA-based therapeutics and gene therapy for rare diseases, similar to Voyager's mission.
PTC Therapeutics
PTCT
Mkt Cap5.85B
PTC Therapeutics is involved in the development of genetically targeted therapies, including for neurological disorders, competing with Voyager.
Novartis
NVS
Mkt Cap292.35B
Novartis has a strong presence in gene therapy, particularly with its acquisition of AveXis, making it a direct competitor in the gene therapy space.
Pfizer
PFE
Mkt Cap159.36B
Pfizer has invested heavily in gene therapy for rare diseases, positioning it as a competitor in the same field as Voyager.
Abeona Therapeutics
ABEO
Mkt Cap338.53M
Abeona Therapeutics focuses on developing gene and cell therapies for serious diseases, making it a competitor in the gene therapy market.

About

Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.
Show more...
CEO
Alfred W. Sandrock Jr.
Employees
141
Country
United States
ISIN
US92915B1061
WKN
000A143XJ

Listings

STU
DE
VT6.STU
MX
MX
VYGR.MX
XNAS
US
VYGR
MU
DE
VT6.MU

0 Comments

Share your thoughts

FAQ

What is Voyager Therapeutics stock price today?▼
The current price of VYGR is $3.38 USD — it has decreased by -4.52% in the past 24 hours. Watch Voyager Therapeutics stock price performance more closely on the chart.
What is Voyager Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Voyager Therapeutics stocks are traded under the ticker VYGR.
Is Voyager Therapeutics stock price growing?▼
VYGR stock has fallen by -4.52% compared to the previous week, the month change is a +8.16% rise, over the last year Voyager Therapeutics has showed a -12.89% decrease.
What is Voyager Therapeutics market cap?▼
Today Voyager Therapeutics has the market capitalization of 208.27M
When is the next Voyager Therapeutics earnings date?▼
Voyager Therapeutics is going to release the next earnings report on November 10, 2026.
What were Voyager Therapeutics earnings last quarter?▼
VYGR earnings for the last quarter are -0.4 USD per share, whereas the estimation was -0.48 USD resulting in a +17.32% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Voyager Therapeutics revenue for the last year?▼
Voyager Therapeutics revenue for the last year amounts to 40.37M USD.
What is Voyager Therapeutics net income for the last year?▼
VYGR net income for the last year is -119.72M USD.
How many employees does Voyager Therapeutics have?▼
As of September 04, 2026, the company has 141 employees.
In which sector is Voyager Therapeutics located?▼
Voyager Therapeutics operates in the Health & Wellness sector.
When did Voyager Therapeutics complete a stock split?▼
Voyager Therapeutics has not had any recent stock splits.
Where is Voyager Therapeutics headquartered?▼
Voyager Therapeutics is headquartered in LEXINGTON, United States.